Drug interactions between tyrosine kinase inhibitors (gefitinib and erlotinib) and warfarin: Assessment of international normalized ratio elevation characteristics and <i>in vitro</i> CYP2C9 activity.

Hiraide, Makoto; Minowa, Yuichi; Nakano, Yasuhiro; Suzuki, Kenichi; Shiga, Taro; Nishio, Makoto; Miyoshi, Junya; Takahashi, Harumi; Hama, Toshihiro

Drug interactions between tyrosine kinase inhibitors (gefitinib and erlotinib) and warfarin: Assessment of international normalized ratio elevation characteristics and in vitro CYP2C9 activity.

Hiraide, Makoto; Minowa, Yuichi; Nakano, Yasuhiro; Suzuki, Kenichi; Shiga, Taro; Nishio, Makoto; Miyoshi, Junya; Takahashi, Harumi; Hama, Toshihiro.

Afiliação

Hiraide M; 1 Department of Pharmacy, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
Minowa Y; 2 Department of Biopharmaceutics, Meiji Pharmaceutical University, Kiyose-city, Tokyo, Japan.
Nakano Y; 1 Department of Pharmacy, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
Suzuki K; 1 Department of Pharmacy, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
Shiga T; 1 Department of Pharmacy, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
Nishio M; 3 Departments of General Medicine and Cardiology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
Miyoshi J; 4 Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
Takahashi H; 2 Department of Biopharmaceutics, Meiji Pharmaceutical University, Kiyose-city, Tokyo, Japan.
Hama T; 2 Department of Biopharmaceutics, Meiji Pharmaceutical University, Kiyose-city, Tokyo, Japan.

J Oncol Pharm Pract ; 25(7): 1599-1607, 2019 Oct.

Article em En | MEDLINE | ID: mdl-30253730

Assuntos

Anticoagulantes/uso terapêutico; Citocromo P-450 CYP2C9/metabolismo; Cloridrato de Erlotinib/uso terapêutico; Gefitinibe/uso terapêutico; Coeficiente Internacional Normatizado; Proteínas Tirosina Quinases/antagonistas & inibidores; Varfarina/uso terapêutico; Adulto; Idoso; Interações Medicamentosas; Feminino; Humanos; Masculino; Pessoa de Meia-Idade; Estudos Retrospectivos

Palavras-chave

CYP2C9 activity; Drug interactions; erlotinib; gefitinib; international normalized ratio; warfarin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Varfarina / Proteínas Tirosina Quinases / Coeficiente Internacional Normatizado / Citocromo P-450 CYP2C9 / Cloridrato de Erlotinib / Gefitinibe / Anticoagulantes Tipo de estudo: Observational_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Oncol Pharm Pract Assunto da revista: FARMACIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google